Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

Christian Todd Nichols, Chief Commercial Officer at Alkermes, sold 7,576 shares of the company's stock on August 17, 2026, for a total value of $373,000. The sale was executed under a pre-approved trading plan, which dictated the shares were to be disposed of over a three-month period prior to the trade. Following the transaction, Nichols retained approximately 102,000 shares, giving him an ownership stake of 0.06% in the company.

At the time of the sale, the stock was trading at a weighted average price of $49.23, slightly lower than its market close price of $49.85. This move represents routine portfolio management for the executive and is not a cause for concern among shareholders. Nichols remains bullish on Alkermes' prospects, with 71% of analysts covering the stock rating it a buy, with a median one-year price target of $59, indicating a potential 24.4% gain from the current price.

Despite the sale, Alkermes continues to generate significant revenue through its focus on neuropsychiatric and neurological disorders, with a market capitalization of $7.9 billion and TTM revenues of $1.7 billion.